Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Imbruvica, PCI 32765
API & Intermediates
KAPI0F17
936563-96-1
MFCD20261150
24821094
.png)
Ibrutinib (also known as Imbruvica, PCI 32765) is a highly selective,irreversible inhibitor of Bruton’s tyrosine kinase (Btk), a member of the BTK/Tec family of protein tyrosine kinases involved in signal transduction pathways regulating proliferation, survival, migration, and tissue homing of B-cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. [1]
Inhibition of IgE-mediated Secretion from Human Basophils with a Highly Selective Bruton’s Tyrosine Kinase, Btk, Inhibitor. [2]
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. [3]
Targeting oncogenic and epigenetic survival pathways in lymphoma. [4]
Novel agents for chronic lymphocytic leukemia. [5]
Novel agents in chronic lymphocytic leukemia. [6]
References:
[1] L.A.Honigbery, et al, Proc. Natl. Acad. Sci. USA, 2010, 107(29), pp 13075-13080.
[2] D.MacGlashan, et al, Int. Immunopharmacol., 2011, 11(4), pp 475-479.
[3] S.E.Herman, et al, Blood, 2011, 117(23), pp 6287-6296.
[4] L.A.Leslie, et al, Leuk. Lymphoma, 2013, 54(1), pp 2365-2376.
[5] M.Wu, et al, J. hematol. Oncol., 2013, 6, pp 36:1-8.
[6] N.Lamanna, et al, Hematology Am. Soc. Hematol. Educ. Program, 2016, 2016(1), pp 137-145.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Warning
H360,H371
P201,P202,P281,P260,P308+P313,P314
NONH for all modes of transport
Sales restrictions may apply.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.